Publications - James L . Slack, M.D.

Back to Research Profile

1. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009 Oct; 94(10):1375-82.
   View PubMed
2. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009 Aug 10; 27(23):3842-8. Epub 2009 Jun 15.
   View PubMed
3. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008 Apr; 32(4):587-91. Epub 2007 Sep 18.
   View PubMed
4. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006 Jun 1; 24(16):2456-64. Epub 2006 May 01.
   View PubMed
5. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 Apr 15; 106(8):1794-803.
   View PubMed
6. Gallagher RE, Schachter-Tokarz EL, Zhou DC, Ding W, Kim SH, Sankoorikal BJ, Bi W, Livak KJ, Slack JL, Willman CL. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia 2006 Apr; 20(4):556-62.
   View PubMed
7. Kantarjian H, Issa JP, Rosenfeld CS, Bennet JM, Albitar M, DiPersio J, Klimek V, Slack J, Ravandi F, Helmer R III, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006; 106:1794-60.
   View PubMed
8. Gallagher RE, Schacter-Tokarz EL, Zhou DC, Ding W, Kim SH, Sankoorikal BJ, Bi W, Livak KJ, Slack JL, Willman CL. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia 2006; 20:556-62.
   View PubMed
9. Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, McCarthy PL, Walsh TJ, Segal BH. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 2005 Feb; 159(2):181-8.
   View PubMed
10. Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuzcman M, McCarthy PL, Walsh TJ, Segal BH. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic and pathologic characteristcs. Mycopathologia 2005; 159(2):181-8.
11. Iyer RV, Sait SN, Matsui S, Block AW, Barcos M, Slack JL, Wetzler M, Baer MR. Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 2004; 148(1):29-34.
    View PubMed
12. Dibo I, Pillai SK, Gold HS, Baer MR, Wetzler M, Slack JL, Hazamy PA, Ball D, Hsiao CB, McCarthy PL Jr, Seagal BH. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 2004; 42(4):1843-5.
    View PubMed
13. Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bamback B, Bernstein ZP, Czuczman MS, Silva J, Slack JL, Wetzler M, Becker J, McCarthy PL Jr. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regiments, unrelated donor, and methylprednisone T-cell depletion. Transplantation 2004; 78(10):1515-22.
    View PubMed
14. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003 Apr 1; 101(7):2521-8.
    View PubMed
15. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003 Apr; 17(4):707-15.
    View PubMed
16. List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P. Opportunities for trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003; 8:1499-1507.
17. Hahn T, Bunworasate U, George MC, Bir AS, Chinratanalaa W, Alam AR, Bambach B, Baer MR, Slack JL, Wetzler M, Becker JL, McCarthy PL Jr. use of nonvolume-reduced (unmanipulated after thawing) umbillical cord blood stem cells for allogeneic transplantation results in safe engraftment. Bone Marrow Transpl 2003; 32(2):145-50.
18. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wezler M, Baer MR. Simvastat-influconazole causing rhabdomyloysis. Ann Pharmacother 2003; 37(7-8):1032-5.
    View PubMed
19. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan AA, Czuczman MS, Slack J, Wetzler M, Mookerjee BK, Silva J, McCarthy Pl Jr. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003; 32(4):405-10.
    View PubMed
20. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002; 7 Suppl 1:1-13.
    View PubMed
21. Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE, Willman CL. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 2001 Nov; 3(4):141-9.
    View PubMed
22. Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, Bambach B, Bernstein SH, Bernstein ZP, Czuczman MS, Slack JL, Wetzler M, Herzig G, Schriber J, McCarthy PL Jr. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001 Mar; 27(6):627-33.
    View PubMed
23. Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000 May; 79(5):227-38.
    View PubMed
24. Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer Res 2000 Apr 1; 60(7):1824-9.
    View PubMed
25. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood 2000 Jan 15; 95(2):398-403.
    View PubMed
26. Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999 Dec; 24(12):1311-4.
    View PubMed
27. Slack JL. Biology and treatment of acute progranulocytic leukemia. Curr Opin Hematol 1999 Jul; 6(4):236-40.
    View PubMed
28. Slack JL. The biology and treatment of acute progranulocytic leukemia. Curr Opin Oncol 1999 Jan; 11(1):9-13.
    View PubMed
29. Slack JL, Gallagher RE. The molecular biology of acute promyelocytic leukemia. Cancer Treat Res 1999; 99:75-124.
    View PubMed
30. Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH, Czuczman MS, Slack JL, Spangenthal E, Wetzler M, Barcos MP, Proulx GM, Anderson B, McCarthy PL Jr. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biology of Blood & Marrow Transplantation 1999; 5(5):322-7.
    View PubMed
31. Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leukemia & Lymphoma 1998 Aug; 30(5-6):415-31.
    View PubMed
32. Slack JL, Yu M. Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis. Blood 1998 May 1; 91(9):3347-56.
    View PubMed
33. Slack JL. Recent advances in the biology and treatment of acute promyelocytic leukemia. J Clin Oncol 1998; 16:54-65.
34. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997 Aug 15; 90(4):1656-63.
35. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol 1997 May; 15(5):1786-95.
    View PubMed
36. Heinonen K, Rao PN, Slack JL, Cruz J, Bloomfield CD, Mrozek K. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol 1996 Jun; 93(3):677-80.
    View PubMed
37. Slack JL, Parker MI, Bornstein P. Transcriptional repression of the alpha 1(I) collagen gene by ras is mediated in part by an intronic AP1 site. J Cell Biochem 1995 Jul; 58(3):380-92.
    View PubMed
38. Slack JL, Bornstein P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth & Differentiation 1994 Dec; 5(12):1373-80.
    View PubMed
39. Slack JL, Liska DJ, Bornstein P. Regulation of expression of the type I collagen genes. Am J Med Genet 1993 Jan 15; 45(2):140-51.
    View PubMed
40. Slack JL, Parker MI, Robinson VR, Bornstein P. Regulation of collagen I gene expression by ras. Mol Cell Biol 1992 Oct; 12(10):4714-23.
    View PubMed
41. Slack JL, Liska DJ, Bornstein P. An upstream regulatory region mediates high-level, tissue-specific expression of the human alpha 1(I) collagen gene in transgenic mice. Mol Cell Biol 1991 Apr; 11(4):2066-74.
    View PubMed
42. Slack JL, Nemunaitis J, Andrews DF 3rd, Singer JW. Regulation of cytokine and growth factor gene expression in human bone marrow stromal cells transformed with simian virus 40. Blood 1990 Jun 15; 75(12):2319-27.
    View PubMed
43. Liska DJ, Slack JL, Bornstein P. A highly conserved intronic sequence is involved in transcriptional regulation of the alpha 1(I) collagen gene. Cell Regul 1990 May; 1(6):487-98.
    View PubMed